June 12, 2018 10:24 AM EDT
R&D

Galmed's stock rock­ets up as ex­ecs tout a mixed set of NASH da­ta

Brittany Meiling

Shares of yet an­oth­er NASH hope­ful are rock­et­ing north this morn­ing, with Tel Aviv-based Galmed post­ing news on its Phase IIb fat­ty liv­er dis­ease drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times